A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)

NCT04751955 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped This clinical trial was not finally approved by the Korea FDA.

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: Olinvacimab added to Capecitabine

Sponsor

Korean Cancer Study Group